181 related articles for article (PubMed ID: 19740997)
1. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.
Hoshino Y; Katano H; Zou P; Hohman P; Marques A; Tyring SK; Follmann D; Cohen JI
J Virol; 2009 Nov; 83(22):11857-61. PubMed ID: 19740997
[TBL] [Abstract][Full Text] [Related]
2. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients.
Ozçay F; Arslan H; Bilezikçi B; Sevmiş S; Moray G; Haberal M
Transplant Proc; 2009 Sep; 41(7):2878-80. PubMed ID: 19765462
[TBL] [Abstract][Full Text] [Related]
3. Response to valacyclovir in an HIV-infected girl with Epstein Barr infection.
Shah I
Indian Pediatr; 2012 May; 49(5):409-10. PubMed ID: 22700667
[TBL] [Abstract][Full Text] [Related]
4. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.
Lerner AM; Beqaj SH; Deeter RG; Dworkin HJ; Zervos M; Chang CH; Fitzgerald JT; Goldstein J; O'Neill W
Drugs Today (Barc); 2002 Aug; 38(8):549-61. PubMed ID: 12582420
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.
Olson D; Gulley ML; Tang W; Wokocha C; Mechanic O; Hosseinipour M; Gold SH; Nguluwe N; Mwansambo C; Shores C
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):112-8. PubMed ID: 23260601
[TBL] [Abstract][Full Text] [Related]
6. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity.
Höllsberg P; Kusk M; Bech E; Hansen HJ; Jakobsen J; Haahr S
Acta Neurol Scand; 2005 Dec; 112(6):395-402. PubMed ID: 16281923
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir.
Walling DM; Flaitz CM; Nichols CM
J Infect Dis; 2003 Sep; 188(6):883-90. PubMed ID: 12964120
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.
Vezina HE; Balfour HH; Weller DR; Anderson BJ; Brundage RC
J Clin Pharmacol; 2010 Jul; 50(7):734-42. PubMed ID: 19897764
[TBL] [Abstract][Full Text] [Related]
10. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo.
Walling DM; Flaitz CM; Nichols CM; Hudnall SD; Adler-Storthz K
J Infect Dis; 2001 Dec; 184(12):1499-507. PubMed ID: 11740724
[TBL] [Abstract][Full Text] [Related]
11. Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners.
Cox AJ; Gleeson M; Pyne DB; Saunders PU; Clancy RL; Fricker PA
Med Sci Sports Exerc; 2004 Jul; 36(7):1104-10. PubMed ID: 15235312
[TBL] [Abstract][Full Text] [Related]
12. Antiviral therapy in children with hydroa vacciniforme.
Lysell J; Wiegleb Edström D; Linde A; Carlsson G; Malmros-Svennilson J; Westermark A; Andersson J; Wahlgren CF
Acta Derm Venereol; 2009; 89(4):393-7. PubMed ID: 19688153
[TBL] [Abstract][Full Text] [Related]
13. [Effect of the Epstein-Barr virus on the nervous system].
Kononenko VV
Lik Sprava; 2001; (4):107-11. PubMed ID: 11692687
[TBL] [Abstract][Full Text] [Related]
14. A virologic pilot study of valacyclovir in infectious mononucleosis.
Balfour HH; Hokanson KM; Schacherer RM; Fietzer CM; Schmeling DO; Holman CJ; Vezina HE; Brundage RC
J Clin Virol; 2007 May; 39(1):16-21. PubMed ID: 17369082
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
In Vivo; 2007; 21(5):707-13. PubMed ID: 18019402
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
17. Persistence and transition of Epstein-Barr virus genotypes in the pathogenesis of oral hairy leukoplakia.
Walling DM; Etienne W; Ray AJ; Flaitz CM; Nichols CM
J Infect Dis; 2004 Jul; 190(2):387-95. PubMed ID: 15216477
[TBL] [Abstract][Full Text] [Related]
18. Patient with severe periodontitis and subgingival Epstein-Barr virus treated with antiviral therapy.
Sunde PT; Olsen I; Enersen M; Grinde B
J Clin Virol; 2008 Jun; 42(2):176-8. PubMed ID: 18304869
[TBL] [Abstract][Full Text] [Related]
19. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
20. Acute retinal necrosis associated with Epstein-Barr virus: immunohistopathologic confirmation.
Schaal S; Kagan A; Wang Y; Chan CC; Kaplan HJ
JAMA Ophthalmol; 2014 Jul; 132(7):881-2. PubMed ID: 24743882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
